Okoliegbe, IjeomaHijazi, KarolinCooper, KimIronside, CorinneGould, Ian M2021-04-192021-04-192020-10Okoliegbe, I, Hijazi, K, Cooper, K, Ironside, C & Gould, I M 2020, 'Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients', Antimicrobial Agents and Chemotherapy, vol. 64, no. 11, e01467-20. https://doi.org/10.1128/AAC.01467-200066-4804ORCID: 0000-0002-7886-7064ORCID: 0000-0002-8589-2129https://hdl.handle.net/2164/16272Acknowledgements: The authors would like to thank the laboratories and clinicians who use the Cystic Fibrosis Antibiotics Susceptibility testing service (CFASS) for their support in sending samples. CFASS is an adult patient testing facility funded by the National Services Division of the Common Services Agency of the Scottish Executive. Achromobacter spp. identification was supported by grants from the University of Aberdeen and the NHS Grampian Clinical Microbiology Fund (NHS Grampian Endowment Funds Registered Charity Number SC017296). IMG serves as a consultant to and/ speaker to Pfizer and MSD. All other authors declare no competing interest10550432engSDG 3 - Good Health and Well-beingAchromobacter sppA. xylosoxidansCystic FibrosisAntimicrobial susceptibility testingSynergy testingEtestRK DentistryR MedicinePharmacology (medical)Infectious DiseasesPharmacologyOtherSC017296RKRJournal article10.1128/AAC.01467-20http://www.scopus.com/inward/record.url?scp=85094219484&partnerID=8YFLogxK6411